U.S. Markets open in 5 hrs 7 mins

Dr. David Kaplan Joins Kraig Biocraft Laboratories Scientific Advisory Board

LANSING, MI--(Marketwire - 06/06/11) - Kraig Biocraft Laboratories, Inc. (Pinksheets:KBLB - News) announced today that celebrated biomedical researcher Dr. David Kaplan, whose research interest focuses on the interface between biology and materials science, with over 35 years of scientific applications research experience, has joined the Company's Board of Scientific Advisors.Dr. Kaplan is internationally recognized for his work relating to biomedical and other applications for spider silk and biopolymers. He is the Chairman of Tufts University's Department of Biomedical Engineering and is the Director of the Bioengineering and Biotechnology Center. His research focus is on biopolymer engineering to understand structure-function relationships, with emphasis on studies related to self-assembly, biomaterials engineering and functional tissue engineering. He has published more than 400 papers and edited eight books.Renowned for his outstanding accomplishments and contributions in the realms of science and biomedical engineering, Dr. Kaplan has been awarded numerous honors and awards including Elected Fellow, American Institute of Medical and Biological Engineering; Outstanding Faculty Award, Tufts University and the Decoration for Meritorious Civilian Service, U.S. Government."We are very happy to announce that Dr. Kaplan has agreed to join our board of Scientific Advisors," said Kraig Biocraft Laboratories founder and CEO, Kim K. Thompson. "There is an obvious synergy between the Kraig's work in developing and producing recombinant spider silk and Dr. Kaplan's work in researching and developing practical applications for biopolymers including spider silk."Thompson continued, "We have always been fortunate in being able to attract the top intellects and talent to both our Scientific Board of Advisors and our Business Board of Advisors. Dr. Kaplan's proven track record in the science of biopolymers and biopolymer applications makes him ideally suited to advise us as we move toward the production of our own spider silk based biopolymers."Additionally, the Company reminds all interested parties that it will host an informational teleconference on Friday, June 10, 2011 at 4:30 p.m. EDT. Interested parties are invited to submit questions to benh@ttfsco.com by Thursday, June 9. Call in details, including phone number and access codes, will be announced in a follow-up company release on the morning of the call.Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information, including videos, which outline the commercial potential that has garnered attention of many scientific and trade journals, please visit www.KraigLabs.com.Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "implications," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.